Aclara Biosciences Overview

  • Founded
  • 1995
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 62
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $180M
Latest Deal Amount

Aclara Biosciences General Information

Description

Developer of advanced tools for drug discovery, genomics and proteomics using its proprietary eTagTM assay chemistries and microfluidics expertise. The company's products allow researchers to have decision-critical information for drug development.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Primary Office
  • 1288 Pear Avenue
  • Mountain View, CA 94043
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aclara Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 10-Dec-2004 $180M 00000 00000 Completed Generating Revenue
9. IPO 21-Mar-2000 00000 00000 Completed Generating Revenue
8. Later Stage VC (Series H) 30-Dec-1999 000 000.00 000.00 Completed Generating Revenue
7. Later Stage VC (Series G) 29-Apr-1999 000 000.00 000.00 Completed Generating Revenue
6. Later Stage VC (Series F) 01-Mar-1999 0000 000.00 000.00 Completed Generating Revenue
5. Later Stage VC (Series E) 01-Apr-1998 00.00 00.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series D) 17-Apr-1997 00000 00.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 01-Nov-1996 00.00 00.00 00.00 Completed Product Development
2. Early Stage VC (Series B) 04-May-1995 $1.4M $3.2M 00.000 Completed Startup
1. Early Stage VC (Series A) 01-May-1995 $1.8M $1.8M 00.000 Completed Startup
To view Aclara Biosciences’s complete valuation and funding history, request access »

Aclara Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series H 000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series G 000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series F1 0,000,000 00.000000 00.00 00.0 00.0 00 00.0
Series F 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series E 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series D 000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series C 1,076,923 $0.001000 $0.1 $1.3 $1.3 1x $1.3 6.75%
Series B 2,344,466 $0.001000 $0.05 $0.6 $0.6 1x $0.6 14.7%
To view Aclara Biosciences’s complete cap table history, request access »

Aclara Biosciences Executive Team (5)

Name Title Board Seat Contact Info
Bruce Phillips Group President
Bruce Kessler President
Terry Messmer Chief Financial Officer & Vice President
Marty Zucker Executive Vice President, Strategic Initiatives
Randy Bell Vice President, Operations
To view Aclara Biosciences’s complete executive team members history, request access »

Aclara Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aclara Biosciences Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alta Partners Venture Capital Minority 000 0000 000000 0
Ampersand Capital Partners Growth/Expansion Minority 000 0000 000000 0
Burrill & Co Merchant Banking Firm Minority 000 0000 000000 0
Gimv PE/Buyout Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »